Literature DB >> 20651901

Eastern Canadian Colorectal Cancer Consensus Conference: setting the limits of resectable disease.

M Vickers1, B Samson, B Colwell, C Cripps, D Jalink, S El-Sayed, E Chen, G Porter, R Goel, J Villeneuve, S Sundaresan, J Asselah, J Biagi, D Jonker, L Dawson, R Letourneau, M Rother, J Maroun, M Thirlwell, M Hussein, M Tehfe, N Perrin, N Michaud, N Hammad, P Champion, R Rajan, R Burkes, S Barrette, S Welch, N Yarom, T Asmis.   

Abstract

The annual Eastern Canadian Colorectal Cancer Consensus Conference was held in Montreal, Quebec, October 22-24, 2009. Health care professionals involved in the care of patients with colorectal cancer participated in presentation and discussion sessions for the purposes of developing the recommendations presented here. This consensus statement addresses current issues in the management colorectal cancer, such as the management of hepatic and pulmonary metastases, the role of monoclonal antibodies to the epidermal growth factor receptor, and the benefits and safety of chemotherapy in elderly patients. The management of gastrointestinal neuroendocrine tumours and gastric cancer are also discussed.

Entities:  

Year:  2010        PMID： 20651901      PMCID： PMC2880907          DOI： 10.3747/co.v17i3.610

Source DB:  PubMed          Journal:  Curr Oncol        ISSN： 1198-0052            Impact factor:   3.677


  56 in total

1.  Long-term results of lung metastasectomy: prognostic analyses based on 5206 cases.

Authors:  U Pastorino; M Buyse; G Friedel; R J Ginsberg; P Girard; P Goldstraw; M Johnston; P McCormack; H Pass; J B Putnam
Journal:  J Thorac Cardiovasc Surg       Date:  1997-01       Impact factor: 5.209

Review 2.  Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data.

Authors:  Anna D Wagner; Wilfried Grothe; Johannes Haerting; Gerhard Kleber; Axel Grothey; Wolfgang E Fleig
Journal:  J Clin Oncol       Date:  2006-06-20       Impact factor: 44.544

3.  Comorbidity, age and overall survival in cetuximab-treated patients with advanced colorectal cancer (ACRC)--results from NCIC CTG CO.17: a phase III trial of cetuximab versus best supportive care.

Authors:  T R Asmis; E Powell; C S Karapetis; D J Jonker; D Tu; M Jeffery; N Pavlakis; P Gibbs; L Zhu; D-A Dueck; R Whittom; C Langer; C J O'Callaghan
Journal:  Ann Oncol       Date:  2010-07-05       Impact factor: 32.976

4.  Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group.

Authors:  Eric Van Cutsem; Vladimir M Moiseyenko; Sergei Tjulandin; Alejandro Majlis; Manuel Constenla; Corrado Boni; Adriano Rodrigues; Miguel Fodor; Yee Chao; Edouard Voznyi; Marie-Laure Risse; Jaffer A Ajani
Journal:  J Clin Oncol       Date:  2006-11-01       Impact factor: 44.544

5.  Phase II study of irinotecan and 5-fluorouracil/leucovorin in patients with primary refractory or relapsed advanced oesophageal and gastric carcinoma.

Authors:  L Assersohn; G Brown; D Cunningham; C Ward; J Oates; J S Waters; M E Hill; A R Norman
Journal:  Ann Oncol       Date:  2004-01       Impact factor: 32.976

6.  Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.

Authors:  Leonard B Saltz; Stephen Clarke; Eduardo Díaz-Rubio; Werner Scheithauer; Arie Figer; Ralph Wong; Sheryl Koski; Mikhail Lichinitser; Tsai-Shen Yang; Fernando Rivera; Felix Couture; Florin Sirzén; Jim Cassidy
Journal:  J Clin Oncol       Date:  2008-04-20       Impact factor: 44.544

7.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.

Authors:  Herbert Hurwitz; Louis Fehrenbacher; William Novotny; Thomas Cartwright; John Hainsworth; William Heim; Jordan Berlin; Ari Baron; Susan Griffing; Eric Holmgren; Napoleone Ferrara; Gwen Fyfe; Beth Rogers; Robert Ross; Fairooz Kabbinavar
Journal:  N Engl J Med       Date:  2004-06-03       Impact factor: 91.245

8.  Capecitabine and oxaliplatin for advanced esophagogastric cancer.

Authors:  David Cunningham; Naureen Starling; Sheela Rao; Timothy Iveson; Marianne Nicolson; Fareeda Coxon; Gary Middleton; Francis Daniel; Jacqueline Oates; Andrew Richard Norman
Journal:  N Engl J Med       Date:  2008-01-03       Impact factor: 91.245

9.  Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial.

Authors:  Matthew T Seymour; Timothy S Maughan; Jonathan A Ledermann; Clare Topham; Roger James; Stephen J Gwyther; David B Smith; Stephen Shepherd; Anthony Maraveyas; David R Ferry; Angela M Meade; Lindsay Thompson; Gareth O Griffiths; Mahesh Kb Parmar; Richard J Stephens
Journal:  Lancet       Date:  2007-07-14       Impact factor: 79.321

10.  TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system.

Authors:  G Rindi; G Klöppel; H Alhman; M Caplin; A Couvelard; W W de Herder; B Erikssson; A Falchetti; M Falconi; P Komminoth; M Körner; J M Lopes; A-M McNicol; O Nilsson; A Perren; A Scarpa; J-Y Scoazec; B Wiedenmann
Journal:  Virchows Arch       Date:  2006-09-12       Impact factor: 4.064
View more
  6 in total

1.  Characteristics affecting survival after locally advanced colorectal cancer in Quebec.

Authors:  L Perron; J M Daigle; N Vandal; M H Guertin; J Brisson
Journal:  Curr Oncol       Date:  2015-12       Impact factor: 3.677

2.  Eastern Canadian Colorectal Cancer Consensus Conference: standards of care for the treatment of patients with rectal, pancreatic, and gastrointestinal stromal tumours and pancreatic neuroendocrine tumours.

Authors:  T Di Valentin; J Biagi; S Bourque; R Butt; P Champion; V Chaput; B Colwell; C Cripps; M Dorreen; S Edwards; C Falkson; D Frechette; S Gill; R Goel; D Grant; N Hammad; A Jeyakumar; M L'espérance; C Marginean; J Maroun; M Nantais; N Perrin; C Quinton; M Rother; B Samson; J Siddiqui; S Singh; S Snow; E St-Hilaire; M Tehfe; M Thirlwell; S Welch; L Williams; F Wright; R Goodwin
Journal:  Curr Oncol       Date:  2013-10       Impact factor: 3.677

3.  Eastern Canadian Colorectal Cancer Consensus Conference 2013: emerging therapies in the treatment of pancreatic, rectal, and colorectal cancers.

Authors:  T Di Valentin; T Asmis; J Asselah; F Aubin; N Aucoin; S Berry; J Biagi; C M Booth; R Burkes; N Coburn; B Colwell; C Cripps; L A Dawson; M Dorreen; D Frechette; R Goel; S Gray; N Hammad; D Jonker; P Kavan; J Maroun; S Nanji; D Roberge; B Samson; M Seal; W Shabana; M Simunovic; S Snow; M Tehfe; M Thirlwell; E Tsvetkova; M Vickers; T Vuong; R Goodwin
Journal:  Curr Oncol       Date:  2016-02-18       Impact factor: 3.677

4.  Eastern Canadian colorectal cancer consensus conference: application of new modalities of staging and treatment of gastrointestinal cancers.

Authors:  T Di Valentin; Y Alam; A Ali Alsharm; S Arif; F Aubin; J Biagi; C M Booth; S Bourque; R Burkes; P Champion; B Colwell; C Cripps; M Dallaire; M Dorreen; N Finn; D Frechette; S Gallinger; J Gapski; C Giacomantonio; S Gill; R Goel; R Goodwin; L Grimard; A Grothey; N Hammad; D Hedley; K Jhaveri; D Jonker; Y Ko; M L'espérance; J Maroun; H Ostic; N Perrin; M Rother; E St-Hilaire; M Tehfe; M Thirlwell; S Welch; N Yarom; T Asmis
Journal:  Curr Oncol       Date:  2012-06       Impact factor: 3.677

Review 5.  Strategies of sequential therapies in unresectable metastatic colorectal cancer: a meta-analysis.

Authors:  T Asmis; S Berry; R Cosby; K Chan; N Coburn; M Rother
Journal:  Curr Oncol       Date:  2014-12       Impact factor: 3.677

6.  Clinical practice guidelines and consensus statements in oncology--an assessment of their methodological quality.

Authors:  Carmel Jacobs; Ian D Graham; Julie Makarski; Michaël Chassé; Dean Fergusson; Brian Hutton; Mark Clemons
Journal:  PLoS One       Date:  2014-10-17       Impact factor: 3.240
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.